<!DOCTYPE html>
<html lang="en-us">

<head>
  <title>More bad news for psychedelic drug company: FDA expands probe after rejection | Ars Technica</title>
<script type="text/javascript">
  ars = {"ASSETS":"https:\/\/cdn.arstechnica.net\/wp-content\/themes\/ars\/assets","HOME_URL":"https:\/\/arstechnica.com","CIVIS":"\/civis","THEME":"light","VIEW":"grid","MOBILE":false,"SUBSCRIBER":false,"PLUS_PLUS":false,"LOGGED":false,"USER_ID":null,"ENV":"production","AD":{"tags":["lykos","maps","mdma","psychedelics","ptsd"],"channel":"science","slug":"more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection","template_type":"article","queue":[],"server":"production"},"TOTAL":113878,"UNREAD":0,"RECENT":[2045537,2045697,2045662,2045671,2045558,2045225,2045628,2045509,2045600,2045569,2044722,2045523,2045525,2045489,2045401,2045482,2045351,2045327,2045406,2045367,2045368,2045340,2045232,2044740,2045243],"LOGINS":true,"CROSS":false,"PARSELY":"arstechnica.com","COMMENTS":false,"HOMEPAGE":false,"SITE":1,"READY":[],"SHOW_ADS":true,"IMG_PROXY":"https:\/\/cdn.arstechnica.net\/i\/","CATEGORY":"science","PAGETITLE":"","ZEN_MODE":false,"MEMO_PID":"62012a7a19351c07620394e0"};
</script>
<link rel="stylesheet" type="text/css" media="all" href="https://cdn.arstechnica.net/wp-content/themes/ars/assets/css/main-b0320f54e6.css" />
    <link rel="alternate" type="application/rss+xml" href="http://feeds.arstechnica.com/arstechnica/index" />
  <link rel="shortcut icon" href="https://cdn.arstechnica.net/favicon.ico" />
  <link rel="icon" type="image/x-icon" href="https://cdn.arstechnica.net/favicon.ico" />
  <link rel="apple-touch-icon" sizes="180x180" href="https://cdn.arstechnica.net/wp-content/themes/ars/assets/img/ars-ios-icon-d9a45f558c.png" />
  <link rel="mask-icon" href="https://cdn.arstechnica.net/wp-content/themes/ars/assets/img/ars-macos-safari-8997f76b21.svg" color="#ff4e00">
  <link rel="icon" sizes="192x192" href="https://cdn.arstechnica.net/wp-content/themes/ars/assets/img/material-ars-db41652381.png" />
  <link rel="me" href="https://mastodon.social/@arstechnica" />

    <meta name="application-name" content="Ars Technica"/>
  <meta name="msapplication-starturl" content="http://arstechnica.com/"/>
  <meta name="msapplication-tooltip" content="Ars Technica: Serving the technologist for 1.2 decades"/>
  <meta name="msapplication-task" content="name=News;action-uri=http://arstechnica.com/;icon-uri=https://cdn.arstechnica.net/favicon.ico"/>
  <meta name="msapplication-task" content="name=Features;action-uri=http://arstechnica.com/features/;icon-uri=https://cdn.arstechnica.net/ie-jump-menu/jump-features.ico"/>
  <meta name="msapplication-task" content="name=OpenForum;action-uri=http://arstechnica.com/civis/;icon-uri=https://cdn.arstechnica.net/ie-jump-menu/jump-forum.ico"/>
  <meta name="msapplication-task" content="name=Subscribe;action-uri=http://arstechnica.com/subscriptions/;icon-uri=https://cdn.arstechnica.net/ie-jump-menu/jump-subscribe.ico"/>


  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta name="advertising" content="ask" />
  <meta property="fb:admins" content="592156917" />
  <meta property="fb:admins" content="108943" />
  <meta property="fb:pages" content="19374573752" />

  <meta name="format-detection" content="telephone=no" />
  <meta name="theme-color" content="#000000" />

  
  <meta name="viewport" content="width=device-width,initial-scale=1">

  <!-- cache hit 8:single/meta:762b8ded7370eaf51000b7a26e7c5f1f -->
<meta name='parsely-page' content='{"title":"More bad news for psychedelic drug company: FDA expands probe after rejection","link":"https:\/\/arstechnica.com\/science\/2024\/08\/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection\/","type":"post","author":"Beth Mole","post_id":2045406,"pub_date":"2024-08-26T21:58:02Z","section":"Science","tags":["lykos","maps","mdma","psychedelics","ptsd","type: report"],"image_url":"https:\/\/cdn.arstechnica.net\/wp-content\/uploads\/2024\/08\/GettyImages-1728618132-150x150.jpg"}'>
<meta name='parsely-metadata' content='{"type":"report","title":"More bad news for psychedelic drug company: FDA expands probe after rejection","post_id":2045406,"lower_deck":"Psychedelic drug company Lykos already slashed staff and overhauled leadership.","image_url":"https:\/\/cdn.arstechnica.net\/wp-content\/uploads\/2024\/08\/GettyImages-1728618132-150x150.jpg","listing_image_url":"https:\/\/cdn.arstechnica.net\/wp-content\/uploads\/2024\/08\/GettyImages-1728618132-360x200.jpg"}'>

  <link rel="canonical" href="https://arstechnica.com/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/" />

<link rel="shorturl" href="https://arstechnica.com/?p=2045406" />

<meta name="description" content="Psychedelic drug company Lykos already slashed staff and overhauled leadership." />

<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:url" content="https://arstechnica.com/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/">
<meta name="twitter:title" content="More bad news for psychedelic drug company: FDA expands probe after rejection">
<meta name="twitter:description" content="Psychedelic drug company Lykos already slashed staff and overhauled leadership.">

<meta name="twitter:site" content="@arstechnica">
<meta name="twitter:domain" content="arstechnica.com">

<meta property="og:site_name" content="Ars Technica" />

<meta name="twitter:image:src" content="https://cdn.arstechnica.net/wp-content/uploads/2024/08/GettyImages-1728618132-760x380.jpg">
  <meta name="twitter:image:width" content="760">
  <meta name="twitter:image:height" content="380">

  <meta name="twitter:creator" content="@BethMarieMole">

<meta property="og:url" content="https://arstechnica.com/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/" />
<meta property="og:title" content="More bad news for psychedelic drug company: FDA expands probe after rejection" />
<meta property="og:image" content="https://cdn.arstechnica.net/wp-content/uploads/2024/08/GettyImages-1728618132-760x380.jpg" />
<meta property="og:description" content="Psychedelic drug company Lykos already slashed staff and overhauled leadership." />
<meta property="og:type" content="article" />
  <!-- cache hit 8:single/header:762b8ded7370eaf51000b7a26e7c5f1f -->
        

<!-- OneTrust Cookies Consent Notice start -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-domain-script="b10882a1-8446-4e7d-bfb2-ce2c770ad910">
</script>
<script id="oneTrustScripts">
    window.OptanonWrapper = function() {
        var CCPAButton = document.getElementById('ot-sdk-btn');
        CCPAButton && CCPAButton.classList.add('ot-sdk-btn--visible');
        window.dataLayer && window.dataLayer.push({
            event: 'OneTrustGroupsUpdated'
        });
        window.cnBus && window.cnBus.emit('onetrust.OneTrustGroupsUpdated');
    };
</script>
<script src="https://cdn.cookielaw.org/opt-out/otCCPAiab.js" ccpa-opt-out-ids="C0002,C0003,C0004,C0005" ccpa-opt-out-geo="ca" ccpa-opt-out-lspa="true">
</script>
<!-- OneTrust Cookies Consent Notice end -->
<!-- Google Tag Manager DataLayer -->
<script>
window.dataLayer = window.dataLayer || [];
window.dataLayer.push({"event":"data-layer-loaded","user":{"ars_userId":undefined,"amg_userId":undefined,"uID":undefined,"sID":undefined,"loginStatus":false,"subscriberStatus":"none","infinityId":undefined,"registrationSource":undefined,"mdw_cnd_id":undefined,"monthlyVisits":undefined,"accessPaywall":undefined,"view":"grid","theme":"light","show_comments":false},"content":{"pageTemplate":"single","pageType":"article|report","contentCategory":"science","section":"science","subsection":undefined,"contributor":"Beth Mole","contentID":2045406,"contentLength":840,"display":"More bad news for psychedelic drug company: FDA expands probe after rejection","contentSource":"web","pageAssets":undefined,"uniqueContentCount":undefined,"monthlyContentCount":undefined,"publishDate":"2024-08-26T21:58:02-04:00","modifiedDate":"2024-08-27T12:36:07-04:00","keywords":"lykos|maps|mdma|psychedelics|PTSD","dataSource":undefined},"marketing":{"campaignName":undefined,"circCampaignId":undefined,"internalCampaignId":undefined,"brand":"Ars Technica","certified_mrc_data":undefined,"condeNastId":undefined},"page":{"pID":undefined,"syndicatorUrl":undefined,"pageURL":"https:\/\/arstechnica.com\/?p=2045406","canonical":"https:\/\/arstechnica.com\/science\/2024\/08\/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection\/","canonicalPathName":"\/science\/2024\/08\/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection\/"},"search":{"facets":undefined,"searchTerms":undefined},"site":{"appVersion":"1.0.0"}});
</script>
<!-- End Google Tag Manager DataLayer -->
<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-NLXNPCQ');</script>
<!-- End Google Tag Manager -->
<!-- Start Headline A/B -->
<script type="text/javascript">
  class ABTest {
    constructor(post_id, init_method) {
      this.post_id = post_id;
      this.ajaxurl = '/services/ars-ajax-handler.php';
      this.expireDays = 1 / 48; // 30 min
      this.group = this.getGroup();
      this.uid = this.getUid();
      this.init_method = init_method;
      this.setTitle();

      if (this.init_method === 'click') {
        this.click();
      } else {
        this.impression();
      }
    }

    setCookie(name, value, days) {
      var expires = "";
      if (days) {
        var date = new Date();
        date.setTime(date.getTime() + (days * 24 * 60 * 60 * 1000));
        expires = "; expires=" + date.toUTCString();
      }
      document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    getCookie(name) {
      var nameEQ = name + "=";
      var ca = document.cookie.split(';');
      for (var i = 0; i < ca.length; i++) {
        var c = ca[i];
        while (c.charAt(0) == ' ') c = c.substring(1, c.length);
        if (c.indexOf(nameEQ) == 0) return c.substring(nameEQ.length, c.length);
      }
      return null;
    }

    // Retrieves a unique id for determining whether the event should be recorded
    getUid() {
      var uid = this.getCookie('ars_ab_' + this.post_id + '_uid');
      if (!uid) {
        uid = (Math.random() + 1).toString(36).substring(2, 7);
        this.setCookie('ars_ab_' + this.post_id + '_uid', uid, this.expireDays);
      }
      return uid;
    };

    // Places the user in either A or B for this post id
    getGroup() {
      var group = this.getCookie('ars_ab_' + this.post_id + '_group');
      if (!group) {
        group = String.fromCharCode(Math.floor(Math.random() * 2) + 65).toLowerCase();
        this.setCookie('ars_ab_' + this.post_id + '_group', group, this.expireDays);
      }
      return group;
    };

    // Records a headline impression (from homepage or other listing)
    impression() {
      // Send fake ajax
      var params = {
        nonce: 'd747e25146',
        action: 'ars_ab_impression',
        id: this.post_id,
        group: this.group,
        uid: this.uid,
        ts: (new Date()).getTime()
      };
      var url = this.ajaxurl + '?' + this.encodeParams(params);
      document.write('\x3Cscript type="text/javascript" src="' + url + '">\x3C/script>');
    };

    // Records a headline click from the actual post page
    click() {
      // Send fake ajax
      var params = {
        nonce: 'a9f154c155',
        action: 'ars_ab_click',
        id: this.post_id,
        group: this.group,
        uid: this.uid,
        ts: (new Date()).getTime()
      };
      var url = this.ajaxurl + '?' + this.encodeParams(params);
      document.write('\x3Cscript type="text/javascript" src="' + url + '">\x3C/script>');
    };

    // If user is in B group, dynamically set title
    setTitle() {
      if (this.group == 'b') {
        var span = document.getElementById('ars_ab_' + this.post_id);
        var title = span.parentNode;
        title.innerHTML = span.getAttribute('data-title-b');
      }
    };

    encodeParams(data) {
      var ret = [];
      for (var d in data)
        ret.push(encodeURIComponent(d) + "=" + encodeURIComponent(data[d]));
      return ret.join("&");
    };

  };
</script>
<!-- End Headline A/B -->
<script>
  window.permutiveCohorts = {"cached_until":{"date":"2024-08-28 02:01:19.921566","timezone_type":3,"timezone":"UTC"},"cohorts":["byfz","butb","bvcs","bvfl","bvgx","bvko","bvnu","bvfe","bvom","bvez","bvqj","bvmj","bvfz","bvny","bvgq","buze","bvmx","bvfm","bvcu","bjfa","bvnd","bvnq","bvvp","bvpy","byfu","bvru","bvej","bvne","bvid","bute","buzf","bvmy","bvpr","bvkf","byoo","bvrj","bvpv","bvhu","bvnc","bvic","bvrn","bvkr","bvgt","bvqd","bvpt","bvld","bvqp","bvfo","bvob","busz","bvgv","bvpg","bvkg","bvfg","bvdx","bvbw","bvns","bvmr","bvki","butc","bveo","bvoz","bvlm","busy","bvoa","bvet","bvcm","bvkq","bvcp","bvnx","bvqb","bvig","bvcg","bvct","bvpe","bvgc"],"gam":["butb","bvrj","bvcs","bvfl","bvgx","bvko","bvnu","bvfe","bvom","bvez","bvqj","bvmj","bvfz","bvny","bvgq","buze","bvmx","bvfm","bvcu","bjfa","bvnd","bvnq","bvvp","bvpy","bvru","bvej","bvne","bvid","bute","buzf","bvmy","bvpr","bvkf","bvpv","bvhu","bvnc","bvic","bvrn","bvkr","bvgt","bvqd","bvpt","bvld","bvqp","bvfo","bvob","busz","bvgv","bvpg","bvkg","bvfg","bvdx","bvbw","bvns","bvmr","bvki","butc","bveo","bvoz","bvlm","busy","bvoa","bvet","bvcm","bvkq","bvcp","bvnx","bvqb","bvig","bvcg","bvct","bvpe","bvgc"],"xandr":[]};
  window.permutiveContextInfo = {"pageProperties":{"client":{"url":"https:\/\/arstechnica.com\/science\/2024\/08\/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection\/","referrer":"","type":"web","user_agent":"AHC\/2.1","domain":"arstechnica.com","title":"More bad news for psychedelic drug company: FDA expands probe after rejection &#8211; Ars Technica"},"type":"article","article":{"id":"2045406","category":"science","subcategory":"","title":"More bad news for psychedelic drug company: FDA expands probe after rejection","tags":["lykos","maps","mdma","psychedelics","ptsd"]}},"url":"https:\/\/arstechnica.com\/science\/2024\/08\/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection\/"};
</script>
<script src="https://www.googletagservices.com/tag/js/gpt.js" id="gpt-script" async></script>
<script>
  window.googletag = window.googletag || {};
  window.googletag.cmd = window.googletag.cmd || [];
  window.cns = window.cns || {};
  window.cns.queue = [];
  window.cns.async = function(s, c) {
    cns.queue.push({
      service: s,
      callback: c
    })
  };
</script>
<script>
  window.cns.pageContext = {"contentType":"article","templateType":"article","channel":"science","subChannel":"","slug":"more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection","server":"production","keywords":{"tags":["lykos","maps","mdma","psychedelics","ptsd"],"cm":[],"platform":["wordpress"],"copilotid":""}};
</script>
<script src="https://ads-static.conde.digital/production/cns/builds/ars-technica/ars-technica.min.js" async></script>
<script type="text/javascript" src="https://cdn.arstechnica.net/wp-content/themes/ars/assets/js/ars-dc1d08cbd8.ads.us.js"></script>
  <script type="text/javascript">!(function(o,_name){function n(){(n.q=n.q||[]).push(arguments)}n.v=1,o[_name]=o[_name]||n;!(function(o,t,n,c){function e(n){(function(){try{return(localStorage.getItem("v4ac1eiZr0")||"").split(",")[4]>0}catch(o){}return!1})()&&(n=o[t].pubads())&&n.setTargeting("admiral-engaged","true")}(c=o[t]=o[t]||{}).cmd=c.cmd||[],typeof c.pubads===n?e():typeof c.cmd.unshift===n?c.cmd.unshift(e):c.cmd.push(e)})(window,"googletag","function");})(window,String.fromCharCode(97,100,109,105,114,97,108));!(function(t,c,i){i=t.createElement(c),t=t.getElementsByTagName(c)[0],i.async=1,i.src="https://shiverscissors.com/v2fumwIJOo-LsCB0dlG18VSTW43CpWhUEPJuKeRTzrEQdSPPlMr5GymU",t.parentNode.insertBefore(i,t)})(document,"script");</script>

  <!-- Taboola -->
  <script type="text/javascript">
    window._taboola = window._taboola || [];
    _taboola.push({
      article: 'auto'
    });
    ! function(e, f, u, i) {
      if (!document.getElementById(i)) {
        e.async = 1;
        e.src = u;
        e.id = i;
        f.parentNode.insertBefore(e, f);
      }
    }(document.createElement('script'),
      document.getElementsByTagName('script')[0],
      '//cdn.taboola.com/libtrc/condenast1-network/loader.js',
      'tb_loader_script');
    if (window.performance && typeof window.performance.mark == 'function') {
      window.performance.mark('tbl_ic');
    }
  </script>
  <meta name='robots' content='max-image-preview:large' />
<link rel='dns-prefetch' href='//cdn.arstechnica.net' />
<link rel='dns-prefetch' href='//s.w.org' />
<link rel='dns-prefetch' href='//arstechnica-apps.s3.amazonaws.com' />
<link rel='stylesheet' id='wp-block-library-css'  href='https://cdn.arstechnica.net/wp/wp-includes/css/dist/block-library/style.min.css?ver=6.0.3' type='text/css' media='all' />
<style id='global-styles-inline-css' type='text/css'>
body{--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--duotone--dark-grayscale: url('#wp-duotone-dark-grayscale');--wp--preset--duotone--grayscale: url('#wp-duotone-grayscale');--wp--preset--duotone--purple-yellow: url('#wp-duotone-purple-yellow');--wp--preset--duotone--blue-red: url('#wp-duotone-blue-red');--wp--preset--duotone--midnight: url('#wp-duotone-midnight');--wp--preset--duotone--magenta-yellow: url('#wp-duotone-magenta-yellow');--wp--preset--duotone--purple-green: url('#wp-duotone-purple-green');--wp--preset--duotone--blue-orange: url('#wp-duotone-blue-orange');--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
</style>
<link rel='stylesheet' id='article_forum_connect_comments-css'  href='https://cdn.arstechnica.net/wp-content/plugins/article-forum-connect/public/css/comments.css?ver=1.2.2' type='text/css' media='all' />
<link rel='stylesheet' id='article_forum_connect_paywall-css'  href='https://cdn.arstechnica.net/wp-content/plugins/article-forum-connect/public/css/paywall.css?ver=1.2.2' type='text/css' media='all' />
<meta property="article:published_time" content="2024-08-26T21:58:02+00:00">
<meta property="article:modified_time" content="2024-08-27T12:36:07+00:00">
<meta name="twitter:partner" content="tfwp" />
<!--
	generated 39 seconds ago
	generated in 0.254 seconds
	served from batcache in 0.003 seconds
	expires in 261 seconds
	billboard: forced 
	view: grid 
	theme: light 
 -->
</head>

<body class="post-template-default single single-post postid-2045406 single-format-standard grid-view light blog-us">
  <!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NLXNPCQ" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->

      	<aside class="ad ad_crown" aria-label="Top of page advertisement"></aside>
  
  <div class="site-wrapper">
    <a class="screen-reader-text skip-link" href="#main" aria-label="Skip to main content">Skip to main content</a>
    <header class="site-header">
      <div class="header-left">
        <a href="https://arstechnica.com" id="header-logo" title="Ars Technica Homepage">
      <span class="icon icon-logo-ars-us"></span>
  </a>
      </div>

      <div class="header-right">
        <nav id="header-nav-primary">
          <ul>
            
  <li><a class="nav-link section-information-technology " href="/information-technology/">Biz &amp; IT</a></li>
  <li><a class="nav-link section-gadgets " href="/gadgets/">Tech</a></li>
  <li><a class="nav-link section-science active" href="/science/">Science</a></li>
  <li><a class="nav-link section-tech-policy " href="/tech-policy/">Policy</a></li>
  <li><a class="nav-link section-cars " href="/cars/">Cars</a></li>
  <li><a class="nav-link section-gaming " href="/gaming/">Gaming &amp; Culture</a></li>
  <li><a class="nav-link store" href="/store/">Store</a></li>
  <li><a class="nav-link forums" href="/civis/">Forums</a></li>
          </ul>
        </nav>

                              <a href="/store/product/subscriptions/" class="header-highlight-link">Subscribe</a>
                                  <div class="dropdown" id="header-search">
          <a href="/search/" class="dropdown-toggle search-toggle" aria-label="Search" aria-expanded="false">
            <span class="icon icon-search-mag-glass"></span>
          </a>
          <div class="dropdown-content">
            <form action="/search/" method="GET" id="search_form">
  <input type="hidden" name="ie" value="UTF-8">
  <input type="text" name="q" id="hdr_search_input" value="" aria-label="Search..." placeholder="Search...">
</form>
<a class="nav-search-close">Close</a>
          </div>
        </div>
        <div class="dropdown dropdown-mega" id="header-burger">
          <a href="#site-menu" class="dropdown-toggle" aria-label="Menu" aria-expanded="false">
            <span></span>
          </a>
          <div id="site-menu" class="dropdown-content">
            <section class="burger-navigate">
  <h3>
    <span class="icon icon-half-target"></span>
    Navigate
  </h3>
  <ul>
          <li><a class="nav-link store" href="/store/">Store</a></li>
      <li><a class="nav-link subscribe" href="/store/product/subscriptions/">Subscribe</a></li>
        <li><a class="nav-link videos" href="http://arstechnica.com/video/">Videos</a></li>
    <li><a class="nav-link section-features" href="/features/">Features</a></li>
    <li><a class="nav-link section-reviews" href="/reviews/">Reviews</a></li>
  </ul>

  <ul>
    <li><a class="nav-link page-rss-feeds" href="/rss-feeds/">RSS Feeds</a></li>
    <li><a class="nav-link mobile" href="/?view=mobile">Mobile Site</a></li>
  </ul>

  <ul>
    <li><a class="nav-link page-about-us" href="/about-us/">About Ars</a></li>
    <li><a class="nav-link page-staff-directory" href="/staff-directory/">Staff Directory</a></li>
    <li><a class="nav-link page-contact-us" href="/contact-us/">Contact Us</a></li>
  </ul>

  <ul>
    <li><a class="nav-link page-advertise-with-us" href="https://advertising.condenast.com/brands/ars-technica">Advertise with Ars</a></li>
    <li><a class="nav-link page-reprints" href="/reprints/">Reprints</a></li>
  </ul>
</section>

<section class="burger-filter">
  <h3>
    <span class="icon icon-half-mag"></span>
    Filter by topic
  </h3>
  <ul id="burger-nav-primary">
    
  <li><a class="nav-link section-information-technology " href="/information-technology/">Biz &amp; IT</a></li>
  <li><a class="nav-link section-gadgets " href="/gadgets/">Tech</a></li>
  <li><a class="nav-link section-science active" href="/science/">Science</a></li>
  <li><a class="nav-link section-tech-policy " href="/tech-policy/">Policy</a></li>
  <li><a class="nav-link section-cars " href="/cars/">Cars</a></li>
  <li><a class="nav-link section-gaming " href="/gaming/">Gaming &amp; Culture</a></li>
  <li><a class="nav-link store" href="/store/">Store</a></li>
  <li><a class="nav-link forums" href="/civis/">Forums</a></li>
  </ul>
</section>

<section class="burger-settings">
  <h3>
    <span class="icon icon-half-gear"></span>
    Settings
  </h3>
  <div>
    <div class="burger-layout">
      
<p>Front page layout</p>
<div class="burger-layout-grid">
  <a rel="nofollow" href="/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/?view=grid">
    <span class="icon icon-grid"></span><br>
    Grid
    <div class="faux-radio active"></div>
  </a>
</div>

<div class="burger-layout-list">
  <a rel="nofollow" href="/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/?view=archive">
    <span class="icon icon-list"></span><br>
    List
    <div class="faux-radio "></div>
  </a>
</div>

    </div>
    <div class="burger-theme">
      <p>Site theme</p>
  <div class="burger-theme-light">
    <a rel="nofollow" href="/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/?theme=light">
      <span><span>light</span></span>
      <div class="faux-radio active"></div>
    </a>
  </div>
  <div class="burger-theme-dark">
    <a rel="nofollow" href="/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/?theme=dark">
      <span><span>dark</span></span>
      <div class="faux-radio "></div>
    </a>
  </div>
    </div>
  </div>
</section>
          </div>
        </div>
              <a class="navlink login-link" href="https://arstechnica.com/civis/login?_xfRedirect=%2Fscience%2F2024%2F08%2Fmore-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection%2F">
      Sign in
    </a>
  
        </div>
    </header>

              
    <main id="main" class="content-wrapper">

<script type="text/javascript">
  ars.ARTICLE = {"url":"https:\/\/arstechnica.com\/science\/2024\/08\/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection\/","short_url":"https:\/\/arstechnica.com\/?p=2045406","title":"More bad news for psychedelic drug company: FDA expands probe after rejection","author":509873,"authorName":"Beth Mole","pubDate":"2024-08-26T21:58:02Z","id":2045406,"topic":1502580,"pages":1,"current_page":1,"superscroll":true,"promoted":[],"single_page":false,"comments":92,"fullwidth":false,"slug":"more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection","arsStaff":{"104481":{"name":"Aaron Zimmerman","title":"Copy Chief","staff":true},"332715":{"name":"Andrew Cunningham","title":"Senior Technology Reporter","staff":true},"855306":{"name":"Ashley Belanger","title":"Senior Policy Reporter","staff":true},"1002":{"name":"Aurich Lawson","title":"Creative Director","staff":true},"857898":{"name":"Benj Edwards","title":"Senior AI Reporter","staff":true},"509873":{"name":"Beth Mole","title":"Senior Health Reporter","staff":true},"453791":{"name":"Cathleen O'Grady","title":"Contributing science reporter","staff":false},"102179":{"name":"Chris Lee","title":"Associate writer","staff":true},"329388":{"name":"Dan Goodin","title":"Senior Security Editor","staff":true},"254631":{"name":"Diana Gitig","title":"Associate Writer","staff":false},"25862":{"name":"Eric Bangeman","title":"Managing Editor","staff":true},"512413":{"name":"Eric Berger","title":"Senior Space Editor","staff":true},"46707":{"name":"Iljitsch van Beijnum","title":"Associate Writer","staff":false},"316010":{"name":"Jason Marlin","title":"Technical Director","staff":true},"746799":{"name":"Jennifer Ouellette","title":"Senior Writer","staff":true},"15365":{"name":"Jeremy Reimer","title":"Senior Niche Technology Historian","staff":false},"52979":{"name":"John Timmer","title":"Senior Science Editor","staff":true},"312082":{"name":"Jon Brodkin","title":"Senior IT Reporter","staff":true},"14317":{"name":"Jonathan M. Gitlin","title":"Automotive Editor","staff":true},"998":{"name":"Ken Fisher","title":"Editor in Chief","staff":true},"440179":{"name":"Kerry Staurseth","title":"Associate Copyeditor","staff":true},"856780":{"name":"Kevin Purdy","title":"Senior Technology Reporter","staff":true},"328283":{"name":"Kyle Orland","title":"Senior Gaming Editor","staff":true},"10243":{"name":"Lee Hutchinson","title":"Senior Technology Editor","staff":true},"173191":{"name":"Matthew Lasar","title":"Associate writer","staff":true},"182268":{"name":"Nate Anderson","title":"Deputy Editor","staff":true},"1991":{"name":"Ohrmazd","title":"","staff":false},"588289":{"name":"Samuel Axon","title":"Senior Editor","staff":true},"294205":{"name":"Scott K. Johnson","title":"Associate Writer","staff":true},"173910":{"name":"Timothy B. Lee","title":"Senior tech policy reporter","staff":false}},"tags":["lykos","maps","mdma","psychedelics","ptsd"],"zen_mode":false};
</script>

<article itemscope itemtype="http://schema.org/NewsArticle" class="article-single standalone intro-standard " id="">
      <div class="column-wrapper">
    <div class="left-column">
        <header class="article-header">
            <h4 class="post-upperdek">
      trippy trip up    &mdash;
</h4>
            <h1 itemprop="headline">More bad news for psychedelic drug company: FDA expands probe after rejection</h1>
            <h2 itemprop="description">Psychedelic drug company Lykos already slashed staff and overhauled leadership.</h2>
            <section class="post-meta">

  
<p class="byline" itemprop="author creator" itemscope itemtype="http://schema.org/Person">
      <a itemprop="url" href="https://arstechnica.com/author/beth/"  rel="author" ><span itemprop="name">Beth Mole</span></a>
    -    <time class="date" data-time="1724709482" datetime="2024-08-26T21:58:02+00:00">Aug 26, 2024 9:58 pm UTC</time>
</p>

  
</section>        </header>
        <section class="article-guts">
            <div itemprop="articleBody" class="article-content post-page">
                                    
<figure class="intro-image intro-left">
  <img src="https://cdn.arstechnica.net/wp-content/uploads/2024/08/GettyImages-1728618132-800x552.jpg" alt="President of Multidisciplinary Association for Psychedelic Studies (MAPS) Rick Doblin speaks onstage during the 2023 Concordia Annual Summit at Sheraton New York on September 18, 2023, in New York City.">
      <figcaption class="caption"><div class="caption-text"><a href="https://cdn.arstechnica.net/wp-content/uploads/2024/08/GettyImages-1728618132-scaled.jpg" class="enlarge-link" data-height="1766" data-width="2560">Enlarge</a> <span class="sep">/</span> President of Multidisciplinary Association for Psychedelic Studies (MAPS) Rick Doblin speaks onstage during the 2023 Concordia Annual Summit at Sheraton New York on September 18, 2023, in New York City.</div><div class="caption-credit"><a rel="nofollow" class="caption-link" href="https://www.gettyimages.com/detail/news-photo/president-multidisciplinary-association-for-psychedelic-news-photo/1728618132?adppopup=true">Getty | John Lamparski</a></div></figcaption>  </figure>

  <aside id="social-left" class="social-left" aria-label="Read the comments or share this article">
          <a class="comment-count icon-comment-bubble-down" href="https://arstechnica.com/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/?comments=1">
      <h4 class="comment-count-before">reader comments</h4>
  
  <span class="comment-count-number">92</span>
  </a>
        </aside>




<!-- cache hit 8:single/related:762b8ded7370eaf51000b7a26e7c5f1f --><!-- empty -->
<p>There's more bad news for the company behind an experimental MDMA therapy for post-traumatic stress disorder, which the Food and Drug Administration <a href="https://arstechnica.com/science/2024/08/mdma-for-ptsd-three-studies-retracted-on-heels-of-fda-rejection/">roundly rejected earlier this month</a>.</p>
<p></p><div class="pullbox sidebar story-sidebar right"><div class="story-sidebar-part"><a href="https://arstechnica.com/science/2024/08/mdma-for-ptsd-three-studies-retracted-on-heels-of-fda-rejection/" class="recommendation-further-reading story-sidebar-part-img" style="background-image:url('https://cdn.arstechnica.net/wp-content/uploads/2024/05/GettyImages-129369648-360x200.jpeg');" tabindex="-1" role="presentation" aria-hidden="true"></a><div class="story-sidebar-part-content"><h3>Further Reading</h3><a class="recommendation-further-reading" href="https://arstechnica.com/science/2024/08/mdma-for-ptsd-three-studies-retracted-on-heels-of-fda-rejection/">MDMA for PTSD: Three studies retracted on heels of FDA rejection</a></div></div></div>According to <a href="https://www.wsj.com/health/healthcare/fda-widens-probe-of-ecstasy-based-drug-studies-510307b0">a report from The Wall Street Journal</a>, the FDA is now expanding an investigation into clinical trials behind the experimental psychedelic therapy—even though the agency has already rejected it. Agency investigators reportedly interviewed four additional people last week, asking questions regarding whether the trials underreported side effects.
<p>People involved in the trial have previously alleged, among other things, that ill effects, such as suicidal thoughts, went undocumented, and trial participants were discouraged from reporting them to bolster the chances of FDA approval. Overall, <a href="https://arstechnica.com/science/2024/06/flawed-scandalous-trials-tank-fda-expert-support-for-mdma-therapy/">the MDMA trials faced crushing criticism</a> amid the FDA's review, with outside experts and agency advisers calling out allegations of sexual misconduct at one trial site, as well as flaws in overall trial designs, multiple sources of biases, and claims that the company behind the therapy, Lykos, fostered a cult-like belief in psychedelics.</p>
<p></p><div class="pullbox sidebar story-sidebar right"><div class="story-sidebar-part"><a href="https://arstechnica.com/science/2024/06/flawed-scandalous-trials-tank-fda-expert-support-for-mdma-therapy/" class="recommendation-further-reading story-sidebar-part-img" style="background-image:url('https://cdn.arstechnica.net/wp-content/uploads/2024/06/GettyImages-566464211-360x200.jpeg');" tabindex="-1" role="presentation" aria-hidden="true"></a><div class="story-sidebar-part-content"><h3>Further Reading</h3><a class="recommendation-further-reading" href="https://arstechnica.com/science/2024/06/flawed-scandalous-trials-tank-fda-expert-support-for-mdma-therapy/">Flawed, scandalous trials tank FDA expert support for MDMA therapy</a></div></div></div>According to the Journal, the recent interviews were being conducted by the FDA's Office of Regulatory Affairs, which oversees inspections, and a subdivision of that office called Biomedical Research Monitoring Program, which works to ensure the quality and integrity of data submitted to FDA. Notably, when the agency rejected MDMA, it advised Lykos to conduct a new trial.
<p>While the FDA's rejection and expanded investigation are bad enough for Lykos, the company announced this month that it's <a href="https://news.lykospbc.com/2024-08-15-Lykos-Therapeutics-Announces-Reorganization-to-Address-FDAs-Recent-Decision-on-Midomafetamine-Capsules-for-PTSD">laying off 75 percent of its staff and overhauling its leadership</a>. The moves were in response to the FDA's rejections, the company said. Additionally, a scientific journal retracted three of the company's MDMA studies, citing "protocol violations amounting to unethical conduct" in its trials, echoing claims raised amid the FDA review.</p>
<h2>Troubling roots</h2>
<p>Underpinning the allegations and criticisms against Lykos are its roots in drug advocacy. Lykos is a commercial spinoff of the psychedelic advocacy nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS). For decades, MAPS has worked to legalize psychedelics and <a href="https://maps.org/advancing-research/">research their use as potential treatments</a>, particularly mental health conditions, including PTSD, anxiety, and substance use disorders. MAPS was founded by Rick Doblin, a longtime psychedelic activist and advocate who openly <a href="https://www.nytimes.com/2024/08/23/opinion/psychedelics-mdma-mental-health.html">believes the use of psychedelics will lead to world peace</a>. Amid the leadership overhaul this month, Doblin left his position on Lykos' board.</p>                                                                        <div class="ars-interlude-container"></div>
                                                                                
<p>"After 38 plus years of work, I'm profoundly saddened by the FDA decision around this critically needed therapy, but am heartened that Lykos will still move forward continuing clinical research that addresses the FDA's questions," Doblin said in a statement. "I can speak more freely as a public advocate by resigning from the Lykos Board. The FDA delays make it more important than ever that I work at MAPS toward developing global legal access to MDMA and other psychedelics for public benefit through MAPS' multidisciplinary research, education, and drug policy reform."</p>
<p>Lykos did not immediately respond to Ars' request for comment on the FDA's investigation. In a response to the Journal, a company spokesperson said that "Lykos is committed to engaging with the FDA and addressing any questions it raises." The spokesperson also noted that the company is planning to meet with the FDA about the rejection, which it is appealing.</p>
<p>But, trial participants and outsiders have levied heavy criticism against the company that will likely be hard to move beyond.</p>
<p>"The prospect of a therapy cult guiding a suggestibility-enhancing drug through clinical trials highlights unique risks that have never been publicly discussed," Neşe Devenot, a Johns Hopkins University senior lecturer in the university’s writing program who focuses on the issue of drugs in society, said in public comments prior to the FDA rejection. "The trials should be scrutinized as if Scientology or NXIVM had submitted a new drug application to the FDA."</p>
<p>Those public comments appeared in a damning report from Institute for Clinical and Economic Review, which concluded that there was <a href="https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-publishes-final-evidence-report-on-treatment-for-post-traumatic-stress-disorder/">insufficient evidence to back MDMA-based therapy</a>. According to the Journal report, Devenot was among the people interviewed by FDA investigators recently.</p>
<p>Lykos' saga has been a blow to the psychedelic community in general and to many patients, particularly veterans, who have reported benefits from using MDMA to treat PTSD, a condition in desperate need of effective treatments.</p>
<p>Amid Lykos' troubles, the company has brought in David Hough as senior medical adviser to oversee clinical and regulatory work. Hough is a former vice president at Johnson &amp; Johnson, where he notably helped develop Spravato—esketamine—a compound related to ketamine that was approved for use against treatment-resistant depression in 2019.</p>

                                                </div>

            
            
            
        </section>
    </div>
    <div class="xrail">
        <div class="xrail-content">
            
            
            
                                        
            
                            <aside class="ad ad_xrail ad_xrail_top ad_xrail_last" aria-label="Top sidebar advertisement"></aside>
                    </div>
    </div>
</div>

<div class="column-wrapper">
    <div class="left-column">
        <div id="social-footer">
                  <a class="comment-count icon-comment-bubble-down" href="https://arstechnica.com/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/?comments=1">
      <h4 class="comment-count-before">reader comments</h4>
  
  <span class="comment-count-number">92</span>
  </a>
          </div>
                    <!-- cache hit 8:single/author:e25d459d6a94dcd7c0e1f1ef4a380ce3 -->  <section class="article-author">
          <a style="background-image:url('https://cdn.arstechnica.net/wp-content/uploads/2016/05/b.mole-45957.jpg');" class="author-photo" href="/author/beth" tabindex="-1" role="presentation" aria-hidden="true"></a>
    
    <div class="author-bio">
      <section class="author-bio-top">
        <a href="/author/beth" class="author-name">Beth Mole</a>
        Beth is Ars Technica’s Senior Health Reporter. Beth has a Ph.D. in microbiology from the University of North Carolina at Chapel Hill and attended the Science Communication program at the University of California, Santa Cruz. She specializes in covering infectious diseases, public health, and microbes.      </section>
    </div>

  </section>
            </div>
    <div class="xrail"></div>
</div>
<div id="article-footer-wrap">
            <aside class="ad_wrapper" aria-label="Full width advertisement">
    <span class="ad_notice">Advertisement </span>        
    <div class="ad ad_fullwidth fullwidth"></div>
</aside>
    
            <section id="comments-area" class="comments-area column-wrapper">
      <div class="row comments-row left-column">
      <a name="comments-bar"></a>
      
<div class="wp-forum-connect-container">

    

    
</div>

    </div>
          <div class="xrail xrail-comments">
        <div class="xrail-content-wrapper">
          <div class="xrail-content xrail-content-comments">
            <aside class="ad ad_xrail ad_xrail_comments" aria-label="Comments sidebar advertisement"></aside>
          </div>
        </div>
                  <div class="xrail-content-wrapper xrail-content-wrapper-bottom">
            <div class="xrail-content xrail-content-comments">
              <aside class="ad ad_xrail ad_xrail_comments" aria-label="Comments sidebar advertisement"></aside>
            </div>
          </div>
              </div>
      </section>
                    <section class="inline-playlist">
  <div class='ars-video-playlist'>
    <h3 class="ars-video-playlist-module-header">Channel <span>Ars Technica</span></h3>
    <div class='ars-video-playlist-module' data-playlist-id='arstechnica-channel-ars-science' data-video-options='[]'></div>
  </div>
</section>
                <div class="prev-next-links">
  <a href="https://arstechnica.com/gadgets/2024/08/samsung-tvs-will-get-7-years-of-updates-starting-with-2023-models/" rel="prev"><span class="arrow">&larr;</span> Previous story</a>  <a href="https://arstechnica.com/information-technology/2024/08/hobbyists-discover-how-to-insert-custom-fonts-into-ai-generated-images/" rel="next">Next story <span class="arrow">&rarr;</span></a></div>
        <footer id="article-footer">
  <div class="recommendations-footer">
    <div id="story-recommendations">
  <div class="heading-column">
    <h3>Related Stories</h3>
  </div>
  <ul id="story-recs" class="rec-wrap"></ul>
</div>
  </div>
      <div id="taboola-below-article-thumbnails---at"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
  _taboola.push({
    mode: 'thumbnails-a-6x1',
    container: 'taboola-below-article-thumbnails---at',
    placement: 'Below Article Thumbnails - AT',
    target_type: 'mix'
  });
</script>
    <div class="recommendations-footer">
    <div id="latest-stories">
  <div class="heading-column">
    <h3>Today on Ars</h3>
  </div>
  <ul id="latest-recs" class="rec-wrap"></ul>
</div>
  </div>
</footer>
    </div>
  </article>
  </main>

  <footer class="site-footer">
    <nav class="nav-footer">

  <section>
    <ul>
      <li><a href="/store/">Store</a></li>
      <li><a href="/store/product/subscriptions/">Subscribe</a></li>
      <li><a href="/about-us/">About Us</a></li>
      <li><a href="/rss-feeds/">RSS Feeds</a></li>
      <li><a rel="nofollow" href="/science/2024/08/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection/?view=mobile">View Mobile Site</a></li>
    </ul>
  </section>

  <section>
    <ul>
      <li><a href="/contact-us/">Contact Us</a></li>
      <li><a href="/staff-directory/">Staff</a></li>
      <li><a href="https://advertising.condenast.com/brands/ars-technica">Advertise with us</a></li>
      <li><a href="/reprints/">Reprints</a></li>
    </ul>
  </section>

  <section class="footer-newsletter">
    <div class="newsletter-wrapper">
      <h3>
        <a href="/newsletters/" class="footer-newsletter-sign-up">Newsletter Signup</a>
      </h3>
      <p>Join the Ars Orbital Transmission mailing list to get weekly updates delivered to your inbox. <a href="/newsletters/" class="footer-newsletter-sign-up">Sign me up &rarr;</a></p>

      <div class="footer-social-links">
        <a href="https://twitter.com/arstechnica" class="footer-social-twitter">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M16.3,28.1c7.5,0,11.7-6.3,11.7-11.7s0-.4,0-.5c.8-.6,1.5-1.3,2-2.1-.7,.3-1.5,.5-2.4,.6,.9-.5,1.5-1.3,1.8-2.3-.8,.5-1.7,.8-2.6,1-.6-.7-1.4-1.1-2.3-1.2s-1.8,0-2.6,.4c-.8,.4-1.4,1.1-1.8,1.9-.4,.8-.5,1.7-.3,2.6-1.6,0-3.2-.5-4.7-1.2-1.5-.7-2.7-1.8-3.8-3-.5,.9-.7,2-.5,3,.2,1,.9,1.9,1.7,2.5-.7,0-1.3-.2-1.9-.5h0c0,1,.3,1.9,.9,2.7,.6,.7,1.4,1.2,2.4,1.4-.6,.2-1.2,.2-1.9,0,.3,.8,.8,1.5,1.5,2s1.5,.8,2.4,.8c-1.5,1.1-3.2,1.8-5.1,1.8-.3,0-.7,0-1,0,1.9,1.2,4.1,1.8,6.3,1.8" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
        <a href="https://mastodon.social/@arstechnica" class="footer-social-mastodon">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M29.3,16.6c0-4.3-2.8-5.6-2.8-5.6-1.4-.7-3.9-.9-6.5-1h0c-2.6,0-5,.3-6.4,1,0,0-2.8,1.3-2.8,5.6s0,2.2,0,3.4c.1,4.2,.8,8.4,4.7,9.5,1.8,.5,3.4,.6,4.6,.5,2.3-.1,3.5-.8,3.5-.8v-1.6c0,0-1.7,.5-3.5,.4-1.8,0-3.7-.2-4-2.4,0-.2,0-.4,0-.6,0,0,1.8,.4,4,.5,1.4,0,2.7,0,4-.2,2.5-.3,4.7-1.8,5-3.3,.4-2.2,.4-5.4,.4-5.4h0Zm-3.4,5.6h-2.1v-5.1c0-1.1-.5-1.6-1.4-1.6s-1.5,.6-1.5,1.9v2.8h-2.1v-2.8c0-1.3-.5-1.9-1.5-1.9s-1.4,.5-1.4,1.6v5.1h-2.1v-5.3c0-1.1,.3-1.9,.8-2.6,.6-.6,1.3-1,2.2-1s1.9,.4,2.4,1.2l.5,.9,.5-.9c.5-.8,1.3-1.2,2.4-1.2s1.7,.3,2.2,1c.6,.6,.8,1.5,.8,2.6v5.3Z" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
        <a href="https://www.facebook.com/arstechnica" class="footer-social-facebook">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M17.3,13.9v2.8h-2v3.4h2v10h4.2v-10h2.8s.3-1.6,.4-3.4h-3.2v-2.3c0-.3,.5-.8,.9-.8h2.3v-3.5h-3.1c-4.4,0-4.3,3.4-4.3,3.9" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
        <a href="https://www.youtube.com/@arstechnica" class="footer-social-youtube">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M29.6,15.2c-.1-.4-.3-.8-.6-1.1-.3-.3-.7-.5-1.1-.7-1.6-.4-7.8-.4-7.8-.4,0,0-6.3,0-7.8,.4-.4,.1-.8,.3-1.1,.7-.3,.3-.5,.7-.6,1.1-.4,1.6-.4,4.8-.4,4.8,0,0,0,3.3,.4,4.8,.1,.4,.3,.8,.6,1.1,.3,.3,.7,.5,1.1,.7,1.6,.4,7.8,.4,7.8,.4,0,0,6.3,0,7.8-.4,.4-.1,.8-.3,1.1-.7s.5-.7,.6-1.1c.4-1.6,.4-4.8,.4-4.8,0,0,0-3.3-.4-4.8m-11.6,7.8v-5.9l5.2,3-5.2,3Z" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
        <a href="https://www.instagram.com/arstechnica/" class="footer-social-instagram">
          <svg style="height: 40px; width: 40px;" id="b" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 40 40">
            <defs>
              <clipPath id="e">
                <rect width="40" height="40" fill="none" />
              </clipPath>
              <clipPath id="f">
                <rect width="40" height="40" fill="none" />
              </clipPath>
            </defs>
            <g id="c">
              <g id="d">
                <g clip-path="url(#e)">
                  <g clip-path="url(#f)">
                    <path d="M20,10c2.7,0,3.1,0,4.1,0,1.1,0,1.8,.2,2.4,.5,.7,.3,1.2,.6,1.8,1.2,.6,.6,.9,1.1,1.2,1.8,.2,.6,.4,1.4,.5,2.4,0,1.1,0,1.4,0,4.1s0,3.1,0,4.1c0,1.1-.2,1.8-.5,2.4-.3,.7-.6,1.3-1.2,1.8-.6,.6-1.1,.9-1.8,1.2-.6,.2-1.4,.4-2.4,.5-1.1,0-1.4,0-4.1,0s-3.1,0-4.1,0c-1.1,0-1.8-.2-2.4-.5-.7-.3-1.3-.6-1.8-1.2-.5-.5-.9-1.1-1.2-1.8-.2-.6-.4-1.4-.5-2.4,0-1.1,0-1.4,0-4.1s0-3.1,0-4.1c0-1.1,.2-1.8,.5-2.4,.3-.7,.6-1.2,1.2-1.8,.6-.6,1.1-.9,1.8-1.2,.6-.2,1.4-.4,2.4-.5,1.1,0,1.4,0,4.1,0m0,2.5c-2.4,0-2.7,0-3.7,0-.9,0-1.4,.2-1.7,.3-.4,.1-.8,.4-1.1,.7-.3,.3-.5,.6-.7,1.1-.1,.3-.3,.8-.3,1.7,0,1,0,1.3,0,3.7s0,2.7,0,3.7c0,.9,.2,1.4,.3,1.7,.2,.4,.4,.7,.7,1.1,.3,.3,.6,.5,1.1,.7,.3,.1,.8,.3,1.7,.3,1,0,1.3,0,3.7,0s2.7,0,3.7,0c.9,0,1.4-.2,1.7-.3,.4-.2,.7-.4,1.1-.7,.3-.3,.5-.6,.7-1.1,.1-.3,.3-.8,.3-1.7,0-1,0-1.3,0-3.7s0-2.7,0-3.7c0-.9-.2-1.4-.3-1.7-.1-.4-.4-.8-.7-1.1-.3-.3-.7-.5-1.1-.7-.3-.1-.8-.3-1.7-.3-1,0-1.3,0-3.7,0m0,2.2c.7,0,1.4,.1,2,.4,.6,.3,1.2,.7,1.7,1.1,.5,.5,.9,1.1,1.1,1.7,.3,.6,.4,1.3,.4,2s-.1,1.4-.4,2c-.3,.6-.7,1.2-1.1,1.7-.5,.5-1.1,.9-1.7,1.1-.6,.3-1.3,.4-2,.4-1.4,0-2.7-.6-3.7-1.5-1-1-1.5-2.3-1.5-3.7s.6-2.7,1.5-3.7,2.3-1.5,3.7-1.5m0,8.3c.8,0,1.5-.3,2.1-.9,.6-.6,.9-1.3,.9-2.1s-.3-1.5-.9-2.1c-.6-.6-1.3-.9-2.1-.9s-1.5,.3-2.1,.9c-.6,.6-.9,1.3-.9,2.1s.3,1.5,.9,2.1c.6,.6,1.3,.9,2.1,.9m6.6-8.1c0,.4-.2,.7-.4,1s-.6,.4-1,.4-.7-.2-1-.4c-.3-.3-.4-.6-.4-1s.2-.7,.4-1c.3-.3,.6-.4,1-.4s.7,.2,1,.4c.3,.3,.4,.6,.4,1" fill="currentColor" />
                  </g>
                </g>
              </g>
            </g>
          </svg>
        </a>
      </div>

    </div>
  </section>
</nav>

<section class="footer-terms-logo">
  <div class="cn-logo">
    <a href="http://condenast.com/" class="icon icon-logo-cn-us" title="Visit Condé Nast"></a>
  </div>

  <p id="copyright-terms">
  CNMN Collection<br>
  WIRED Media Group<br>
  © 2024 Condé Nast. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our <a href="https://www.condenast.com/user-agreement/">User Agreement</a> (updated 1/1/20) and <a href="https://www.condenast.com/privacy-policy/">Privacy Policy</a> and <a href="/amendment-to-conde-nast-user-agreement-privacy-policy/">Ars Technica Addendum</a>. Ars may earn compensation on sales from links on this site. <a href="/affiliate-link-policy/">Read our affiliate link policy</a>.<br>
  <span style="display: inline-flex; flex-flow: row nowrap; align-items: center; gap: 5px;"><a href="https://www.condenast.com/privacy-policy/#california">Your California Privacy Rights</a> | <img src="https://cdn.arstechnica.net/wp-content/themes/ars/assets/img/privacyoptions123x59-c5c9972158.png" style="height: 1em; width: auto;" /> <a id="ot-sdk-btn" class="ot-sdk-show-settings">Do Not Sell My Personal Information</a></span><br>
  The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Condé Nast.<br>
  <a href="https://www.aboutads.info/">Ad Choices</a>
</p>
</section>
  </footer>
  </div>

  <script type="text/javascript" src="https://cdn.arstechnica.net/wp-content/themes/ars/assets/js/main-d1ad651ce0.js"></script>


<!-- cache hit 8:single/javascript-footer:762b8ded7370eaf51000b7a26e7c5f1f -->
        


    <!-- Taboola -->
  <script type="text/javascript">
    window._taboola = window._taboola || [];
    _taboola.push({
      flush: true
    });
  </script>

  <!-- Parse.ly start -->
<script type="text/plain" class="optanon-category-C0002" id="parsely-cfg" src="//fpa-cdn.arstechnica.com/keys/arstechnica.com/p.js"></script>
<!-- Parse.ly end -->

<!-- Memo start -->
<script type="text/javascript">
__memo_config = {
	pid: ars.MEMO_PID,
	url: ars.ARTICLE.url,
	author: [ars.ARTICLE.authorName],
	title: ars.ARTICLE.title,
	date: ars.ARTICLE.pubDate,
};
(function(){
	var s = document.createElement('script'); 
	s.async = true; 
	s.type = 'text/javascript'; 
	s.src = document.location.protocol + '//cdn.memo.co/js/memo.js';
	(document.getElementsByTagName('head')[0] || document.getElementsByTagName('body') [0]).appendChild(s); 
})();
</script>
<!-- Memo end -->

  
  
    
<script>
  // Load the interlude player.
  window.loadInterludePlayer = function() {
    const src = 'https://player.cnevids.com/interlude/arstechnica.js';

    // Test that script isn't already loaded.
    if (document.querySelector('script[src="' + src + '"]')) {
      return;
    }

    const s = document.createElement('script');
    s.setAttribute('async', true);
    s.setAttribute('src', src);
    document.body.appendChild(s);
  };

  (function() {
    // Only load the interlude player if the container is present.
    if (!document.querySelector('.ars-interlude-container')) {
      return;
    }

    // If sponsored, abort.
    if (document.querySelector('body.single-ars_sponsored_post')) {
      return;
    }

    loadInterludePlayer();
  })();
</script>

<script id="conde-polar" src="https://cdn.mediavoice.com/nativeads/script/condenastcorporate/conde-asa-polar-master.js" async></script>
<script type="text/javascript" src="//s.skimresources.com/js/100098X1555750.skimlinks.js"></script>
<script type='text/javascript' id='snowplow-js-before'>
window.snowplowQueue = window.snowplowQueue || []; window.snowplowContexts = {"site":{"orgId":"4gKgcFGUFUvCGFzHakTPfYp85Yi8","orgAppId":null,"appVersion":null,"env":"production"},"content":{"functionalTags":null,"hasBuyButtons":null,"noOfRevisions":null,"editorNames":null,"author_name":"Beth Mole","contentId":"2045406","contentLength":1,"contentTitle":"More bad news for psychedelic drug company: FDA expands probe after rejection","contentSource":"web","authorIds":"45957","publishDate":"2024-08-26T21:58:02Z","modifiedDate":"2024-08-27T12:36:07Z","tags":"lykos|maps|mdma|psychedelics|PTSD","contentLang":"en-US","galleryName":null,"totalGalleryImages":null,"wordCount":759,"contentType":null,"templateType":"article_standard_two_column","primaryTag":null,"contentFlag":"news","isCommerceContent":null,"pageTypeProperties":null,"section":"science","subsection":null,"subsection2":null,"dataSource":"web","content_type":"article"},"syndication":{"content":null,"originalSource":null,"originalContentLanguage":null},"page":{"canonical":"https:\/\/arstechnica.com\/science\/2024\/08\/more-bad-news-for-psychedelic-drug-company-fda-expands-probe-after-rejection\/","syndicatorUrl":null},"user":{"amguuid":null}}; window.snowplowConfig = {"SNOWPLOW_COLLECTOR":"c.arstechnica.com","SNOWPLOW_SCRIPT":"https:\/\/globalservices.conde.digital\/p77xzrbz9z.js","AVO_API_KEY":"FTJO6mVPBIzdGhjn2Ruy","APP_ID":"ars-technica","APP_NAME":"ars-technica","APP_ENV":"production","APP_VERSION":"1.0.0","COOKIE_DOMAIN":".arstechnica.com"};
</script>
<script type='text/javascript' src='https://cdn.arstechnica.net/wp-content/mu-plugins/ars-snowplow/ars-snowplow-js/dist/main-1-0-4.js?ver=1.0.4' id='snowplow-js'></script>
<script type='text/javascript' src='https://cdn.arstechnica.net/wp-content/plugins/article-forum-connect/public/js/iframeResizer.min.js?ver=1.2.2' id='article_forum_connect_iframe_resizer-js'></script>
<script type='text/javascript' src='https://cdn.arstechnica.net/wp-content/plugins/article-forum-connect/public/js/iframe.js?ver=1.2.2' id='article_forum_connect_iframe-js'></script>
  </body>

  </html>